Klaus Pfizenmaier

Klaus Pfizenmaier's AcademicInfluence.com Rankings

Klaus Pfizenmaier

Computer Science

#6530

World Rank

#6883

Historical Rank

Computational Linguistics

#1148

World Rank

#1162

Historical Rank

Machine Learning

#2153

World Rank

#2181

Historical Rank

Artificial Intelligence

#2417

World Rank

#2458

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Klaus Pfizenmaier's Degrees

Masters Computer Science University of Stuttgart
Bachelors Computer Science University of Stuttgart

Similar Degrees You Can Earn

Why Is Klaus Pfizenmaier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klaus Pfizenmaier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tumor necrosis factor signaling (2003) (2387)
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor (1995) (1374)
Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 (2002) (572)
PKCu is a novel, atypical member of the protein kinase C family. (1994) (541)
PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid. (1995) (506)
Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. (1987) (488)
Tumor Necrosis Factor (TNF)-mediated Neuroprotection against Glutamate-induced Excitotoxicity Is Enhanced by N-Methyl-D-aspartate Receptor Activation (2004) (343)
Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes (1977) (322)
Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIβ at the Golgi complex (2005) (289)
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. (2013) (244)
Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. (1987) (240)
Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses (1990) (227)
Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. (1997) (227)
T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice (1980) (219)
T‐T Cell Interactions during Cytotoxic T Lymphocyte (CTL) Responses: T Cell Derived Helper Factor (Interleukin 2) as a Probe to Analyze CTL Responsiveness and Thymic Maturation of CTL Progenitors (1980) (217)
Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative (2001) (215)
Non-apoptotic Fas signaling. (2003) (207)
In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis (1997) (200)
Regulation of secretory transport by protein kinase D–mediated phosphorylation of the ceramide transfer protein (2007) (192)
Protein kinase D regulates vesicular transport by phosphorylating and activating phosphatidylinositol-4 kinase IIIbeta at the Golgi complex. (2005) (170)
Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo (1981) (165)
Protein Kinase D-dependent Phosphorylation and Nuclear Export of Histone Deacetylase 5 Mediates Vascular Endothelial Growth Factor-induced Gene Expression and Angiogenesis* (2008) (162)
TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. (1994) (156)
TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. (1998) (146)
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy (2002) (142)
Tumor therapeutics by design: targeting and activation of death receptors. (2005) (136)
Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. (1990) (130)
TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. (1993) (129)
The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes. (1977) (129)
Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand1 (2009) (127)
Protein Kinase C (PKC)η-mediated PKCμ Activation Modulates ERK and JNK Signal Pathways* (2002) (122)
Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. (1979) (122)
Regulation of Raf‐1 kinase by TNF via its second messenger ceramide and cross‐talk with mitogenic signalling (1998) (121)
Tumor necrosis factor signal transduction. Cell-type-specific activation and translocation of protein kinase C. (1990) (120)
Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration (2016) (113)
Dissection of the proliferative and differentiative signals controlling murine cytotoxic T lymphocyte responses. (1982) (112)
Protein kinase C mu is located at the Golgi compartment (1996) (112)
Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells (2012) (110)
Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L (2007) (110)
Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. (2009) (109)
A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death (2011) (108)
Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis (2002) (108)
Cross-talk mechanisms in the development of insulin resistance of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B (PKB)/Akt stimulation and glucose uptake. (1999) (107)
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability (2005) (104)
Protein Kinase C μ Is Negatively Regulated by 14-3-3 Signal Transduction Proteins* (1999) (101)
Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hybridization. (1989) (97)
Quantification and characterization of high‐affinity membrane receptors for tumor necrosis factor on human leukemic cell lines (1986) (96)
Protein Kinase D Controls Actin Polymerization and Cell Motility through Phosphorylation of Cortactin* (2010) (96)
Tumor Necrosis Factor Induces Ceramide Oscillations and Negatively Controls Sphingolipid Synthases by Caspases in Apoptotic Kym-1 Cells* (1998) (94)
Characterization of activators and inhibitors of protein kinase C mu. (1995) (94)
Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. (1993) (90)
Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. (1988) (90)
Phospho-specific binding of 14-3-3 proteins to phosphatidylinositol 4-kinase III β protects from dephosphorylation and stabilizes lipid kinase activity (2006) (90)
Selective Targeting of TNF Receptors as a Novel Therapeutic Approach (2020) (88)
Astrocyte‐specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor (2014) (87)
Structural requirements for localization and activation of protein kinase C μ (PKCμ) at the Golgi compartment (2002) (87)
Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. (2009) (87)
T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells (1977) (86)
Virus and trinitrophenol hapten-specific T-cell-mediated cytotoxicity against H-2 incompatible target cells (1976) (85)
Protein Kinase C μ Is Regulated by the Multifunctional Chaperon Protein p32* (2000) (82)
Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation* (2003) (82)
Global Detection of Protein Kinase D-dependent Phosphorylation Events in Nocodazole-treated Human Cells* (2012) (81)
An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. (2008) (81)
Differential γ-Interferon Response of Human Colon Carcinoma Cells: Inhibition of Proliferation and Modulation of Immunogenicity as Independent Effects of γ-Interferon on Tumor Cell Growth (1985) (80)
Tumor necrosis factor signal transduction. Tissue-specific serine phosphorylation of a 26-kDa cytosolic protein. (1989) (76)
Membrane Tumor Necrosis Factor (TNF) Induced Cooperative Signaling of TNFR60 and TNFR80 Favors Induction of Cell Death Rather Than Virus Production in HIV-infected T Cells (1997) (75)
Angiotensin II Stimulates Protein Kinase D–Dependent Histone Deacetylase 5 Phosphorylation and Nuclear Export Leading to Vascular Smooth Muscle Cell Hypertrophy (2007) (75)
Cloning and characterization of promoter and 5'-UTR of the NMDA receptor subunit epsilon 2: evidence for alternative splicing of 5'-non-coding exon. (1998) (75)
In vitro activation and substrates of recombinant, baculovirus expressed human protein kinase Cμ (1996) (74)
Protein kinase Cmu downregulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-kappaB-dependent protective genes. (1998) (73)
Superior serum half life of albumin tagged TNF ligands. (2010) (72)
Autocrine stimulation of TNF-alpha mRNA expression in HL-60 cells. (1987) (69)
Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators (1987) (69)
Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. (1989) (67)
Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity1 (2008) (67)
Biological effects of γ‐interferon on human tumor cells: Quantity and affinity of cell membrane receptors for γ‐IFN in relation to growth inhibition and induction of HLA‐DR expression (1985) (67)
Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. (2010) (67)
Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha. (1995) (67)
Tumor necrosis factor inhibits MYC expression in HL-60 cells at the level of mRNA transcription. (1987) (66)
Antagonistic control of tumor necrosis factor receptors by protein kinases A and C. Enhancement of TNF receptor synthesis by protein kinase A and transmodulation of receptors by protein kinase C (1989) (65)
Procaryotic Expression of Single-Chain Variable-Fragment (scFv) Antibodies: Secretion in L-Form Cells of Proteus mirabilis Leads to Active Product and Overcomes the Limitations of Periplasmic Expression in Escherichia coli (1998) (65)
Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. (2002) (65)
Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice (2011) (64)
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins (2010) (63)
Engineering death receptor ligands for cancer therapy. (2013) (63)
In vivo sensitization of T cells to hapten‐conjugated syngeneic structures of major histocompatibility complex. I. Effect of in vitro culture upon generation of cytotoxic T lymphocytes (1976) (61)
Quantitative representation of all T cells committed to develop into cytotoxic effector cells and/or interleukin 2 activity‐producing helper cells within murine T lymphocyte subsets (1984) (60)
Mapping of H–2 genes associated with T cell-mediated cytotoxic responses to SV40–tumour-associated specific antigens (1978) (60)
Identification of Potential Active-site Residues in the Hydroxynitrile Lyase from Manihot esculenta by Site-directed Mutagenesis* (1996) (59)
ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody (2010) (59)
TNF signal transduction and TNF-responsive genes. (1992) (59)
PKD is recruited to sites of actin remodelling at the leading edge and negatively regulates cell migration (2007) (58)
Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization (2008) (57)
Tumour necrosis factor signal transduction. (1990) (57)
Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis (2014) (57)
Tumor necrosis factor-induced changes of gene expression in U937 cells. Differentiation-dependent plasticity of the responsive state. (1988) (56)
TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice (2020) (56)
Molecular cloning of hydroxynitrile lyase from Sorghum bicolor (L.). Homologies to serine carboxypeptidases (1994) (56)
TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. (2013) (56)
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity (2012) (53)
Purification and Characterization of a Novel (R)-Mandelonitrile Lyase from the Fern Phlebodium aureum (1995) (52)
Species-Crossreactive scFv Against the Tumor Stroma Marker “Fibroblast Activation Protein” Selected by Phage Display From an Immunized FAP−/− Knock-Out Mouse (2001) (50)
Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. (2015) (50)
Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. (2004) (50)
Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. (2002) (49)
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor‐targeted TRAIL fusion protein combined with bortezomib (2013) (49)
Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas (2001) (48)
Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases (2014) (48)
Human RERE is localized to nuclear promyelocytic leukemia oncogenic domains and enhances apoptosis. (2001) (48)
Bruton's tyrosine kinase (Btk) associates with protein kinase C μ (1999) (48)
Glycosylation of the human interferon-gamma receptor. N-linked carbohydrates contribute to structural heterogeneity and are required for ligand binding. (1990) (46)
Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug (2006) (46)
Intrathymic differentiation of cytotoxic T lymphocyte (CTL) precursors. I. The CTL immunocompetence of peanut agglutinin-positive (cortical) and negative (medullary) Lyt 123 thymocytes. (1980) (46)
A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. (2006) (45)
Temporary presence of self-reactive cytotoxic T lymphocytes during murine lymphocytic choriomeningitis (1975) (42)
Insulin selectively activates STAT5b, but not STAT5a, via a JAK2‐independent signalling pathway in Kym‐1 rhabdomyosarcoma cells (1999) (42)
Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties (2013) (42)
Preferential H-2 association in cytotoxic T cell responses to SV40 tumor-associated specific antigens. (1980) (42)
Quantitation and Characterization of γ-Interferon Receptors on Human Tumor Cells (1986) (42)
Activation of CD95L fusion protein prodrugs by tumor-associated proteases (2007) (41)
A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action (2008) (40)
TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes (2019) (39)
Regulation of T cell‐mediated cytotoxic allograft responses. I. Evidence for antigen‐specific suppressor T cells (1976) (39)
Protein kinase D controls the integrity of Golgi apparatus and the maintenance of dendritic arborization in hippocampal neurons. (2009) (38)
Antagonistic TNF Receptor One-Specific Antibody (ATROSAB): Receptor Binding and In Vitro Bioactivity (2013) (38)
Dissection of the proliferative and differentiative signals controlling murine cytotoxic T lymphocyte responses (1982) (38)
T-cell-derived helper factor allows Lyt 123 thymocytes to differentiate into cytotoxic T lymphocytes (1979) (38)
Lymphocyte Adhesion to Human Endothelial Cells Induces Tissue Factor Expression via a Juxtacrine Pathway (1995) (38)
Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection. (2001) (36)
Acetone cyanohydrin lyase from Manihot esculenta (cassava) is serologically distinct from other hydroxynitrile lyases (1995) (36)
TNF inhibits insulin induced STAT5 activation in differentiated mouse muscle cells pmi28 (1998) (36)
Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles. (2014) (36)
Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFκB pathway. (2011) (35)
Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. (2005) (35)
Antagonists of TNF action: clinical experience and new developments (2009) (35)
Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. (2001) (34)
EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells (2014) (34)
Signaling by E-selectin and ICAM-1 induces endothelial tissue factor production via autocrine secretion of platelet-activating factor and tumor necrosis factor alpha. (1995) (33)
High affinity human IFN-gamma-binding capacity is encoded by a single receptor gene located in proximity to c-ros on human chromosome region 6q16 to 6q22. (1988) (32)
H-2 restriction as a consequence of intentional priming. Frequency analysis of alloantigen-restricted, trinitrophenyl-specific cytotoxic T lymphocyte precursors within thymocytes of normal mice (1981) (32)
T-T cell interactions during in vitro cytotoxic T lymphocyte responses. V. Precursor frequencies and specificity of alloreactive helper T cells (1982) (32)
H-2 restriction as a consequence of intentional priming: T cells of fully allogeneic chimeric mice as well as of normal mice respond to foreign antigens in the context of H-2 determinants not encountered on thymic epithelial cells. (1980) (31)
Rapid modulation of tumor necrosis factor membrane receptors by activators of protein kinase C. (1986) (31)
Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis (2018) (31)
Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2 (2017) (31)
Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. (2010) (31)
Expression of the Zn2+-containing hydroxynitrile lyase from flax (Linum usitatissimum) in Pichia pastoris— utilization of the recombinant enzyme for enzymatic analysis and site-directed mutagenesis (1998) (31)
Early events during primary activation of T cells: antigen receptor cross‐linking and interleukin 1 initiate proliferative response of human T cells (1985) (30)
Noncytocidal Mechanisms of Action of Tumor Necrosis Factor-α on Human Tumor Cells: Enhancement of HLA Gene Expression Synergistic with Interferon-γ* (1986) (30)
Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma (2018) (29)
A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells. (1997) (29)
Tumor necrosis factors in 1996. (1996) (29)
A Golgi PKD Activity Reporter Reveals a Crucial Role of PKD in Nocodazole‐Induced Golgi Dispersal (2009) (28)
TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor (2002) (28)
Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor. (1999) (28)
Superior Properties of Fc-comprising scTRAIL Fusion Proteins (2017) (27)
T‐T cell interactions during in vitro cytotoxic T lymphocyte responses. III. Antigen‐specific T helper cells release nonspecific mediator(s) able to help induction of H‐2‐restricted cytotoxic T lymphocyte responses across cell‐impermeable membranes (1980) (27)
PMA-responsive 5' flanking sequences of the human TNF gene. (1989) (27)
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis (2014) (27)
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy (2016) (27)
Shared determinants between virus‐infected and trinitrophenyl‐conjugated H‐2‐identical target cells detected in cell‐mediated lympholysis (1976) (26)
Therapeutic targeting of CD95 and the TRAIL death receptors. (2011) (25)
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models (2020) (25)
Alloreactive and H-2-restricted Lyt 23 cytotoxic T lymphocytes derive from a common pool of antecedent Lyt 123 precursors (1980) (25)
Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface (2006) (25)
Expression patterns of protein kinase D 3 during mouse development (2008) (25)
Protein kinase C [micro] is regulated by the multifunctional chaperon protein p32. (2000) (24)
Monitoring of scFv selected by phage display using detection of scFv-pIII fusion proteins in a microtiter scale assay. (1998) (24)
Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities. (1987) (24)
A single-chain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. (1995) (23)
The role of the major histocompatibility gene complex in murine cytotoxic T cell responses. (1980) (23)
Drosophila protein kinase D is broadly expressed and a fraction localizes to the Golgi compartment. (2006) (23)
Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis (2019) (23)
IgG-single-chain TRAIL fusion proteins for tumour therapy (2018) (22)
Tumor necrosis factors in 1998. (1998) (22)
Guided selection of antibody fragments specific for human interferon gamma receptor 1 from a human VH- and VL-gene repertoire. (1998) (22)
Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. (2000) (22)
A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression. (1999) (22)
The in vivo effects of interleukin 2 (TCGF). (1982) (21)
Protein kinase D promotes plasticity-induced F-actin stabilization in dendritic spines and regulates memory formation (2015) (20)
Regulation of IFN-gamma-receptor expression in human monocytes by granulocyte-macrophage colony-stimulating factor. (1990) (20)
Improving TNF as a cancer therapeutic: Tailor‐made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects (2009) (20)
Characterization of different soluble TNF receptor (TNFR80) derivatives: positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. (1996) (19)
A CD40–CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95 (2006) (19)
Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression. (1985) (18)
Modulation of major histocompatibility complex (MHC) class I genes in adenovirus 12 transformed cells: interferon-gamma increases class I expression by a mechanism that circumvents E1A induced-repression and tumor necrosis factor enhances the effect of interferon-gamma. (1989) (18)
Protein kinase D controls voluntary-running-induced skeletal muscle remodelling. (2011) (18)
Long-term NR2B expression in the cerebellum alters granule cell development and leads to NR2A down-regulation and motor deficits (2004) (17)
Regulation of the murine NMDA‐receptor‐subunit NR2C promoter by Sp1 and fushi tarazu factor1 (FTZ‐F1) homologues (1999) (17)
Frequency analysis of cytotoxic T lymphocyte precursors in chimeric mice. Evidence for intrathymic maturation of clonally distinct self- major histocompatibility complex- and allo-major histocompatiblilty complex-restricted virus-specific T cells (1981) (17)
A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells (2020) (16)
Bruton's tyrosine kinase (Btk) associates with protein kinase C mu. (1999) (16)
Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. (1985) (16)
Coexpression of the human TNF receptors TR60 and TR80 in insect cells: analysis of receptor complex formation. (1994) (15)
TNF down-regulation of receptor tyrosine kinase-dependent mitogenic signal pathways as an important step in cytostasis induction and commitment to apoptosis of Kym-1 rhabdomyosarcoma cells (2000) (15)
Primary in vitro sensitization of virus specific cytotoxic T lymphocytes. (1978) (15)
IL-2 production in human T lymphotropic virus I-infected leukemic T lymphocytes analyzed by in situ hybridization. (1988) (15)
Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription (1988) (14)
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein (2017) (14)
The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation (2021) (14)
Murine T cell subsets and interleukins: relationships between cytotoxic T cells, helper T cells and accessory cells. (1982) (14)
Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc (2019) (13)
Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. (2009) (13)
Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: Clinical responsiveness to recombinant ifn‐α correlates with the degree of receptor down‐regulation (1989) (13)
T–T cell collaboration during in vivo responses to antigens coded by the peripheral and central region of the MHC (1976) (13)
Quantitation and characterization of gamma-interferon receptors on human tumor cells. (1986) (13)
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action. (2013) (13)
Cell-mediated allograft responses in vitro. VI. Studies on macrophage-mediated cytotoxicity. (1975) (13)
Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity (2018) (12)
Distinct mechanisms of interferon‐gamma and tumor necrosis factor‐alpha action in oncogene‐transformed mouse fibroblasts (1988) (12)
Human chromosome 21 is necessary and sufficient to confer human IFN gamma responsiveness to somatic cell hybrids expressing the cloned human IFN gamma receptor gene. (1990) (12)
Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma. (1986) (12)
Murine gamma interferon inhibits v-mos-induced fibroblast transformation via down regulation of retroviral gene expression (1987) (12)
Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level. (1988) (12)
G‐PKDrep‐live, a genetically encoded FRET reporter to measure PKD activity at the trans‐Golgi‐network (2012) (11)
Enantioselective Synthesis of Aliphatic (S)‐Cyanohydrins in Organic Solvents Using Hydroxynitrile Lyase from Manihot esculenta (1996) (11)
Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts (1991) (11)
A mouse bone marrow stromal cell line with skeletal stem cell characteristics to study osteogenesis in vitro and in vivo. (2014) (10)
POST‐TRANSCRIPTIONAL DOWNREGULATION OF MHC CLASS I EXPRESSION IN ONCOGENE‐TRANSFORMED CELLS IS REVERTED BY IFN‐GAMMA AND TNF‐ALPHA (1989) (10)
IFN-γ Receptors on Human Tumor Cells: Relationship between Receptor Ligand Interactions and Induction of IFN-γ Response (1986) (9)
Workshop Summary: Introduction to Rational Design of New Means for Therapeutic Modulation of Function of the TNF Family. (2011) (9)
Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies. (1988) (9)
A new tool for the quantitative analysis of dendritic filopodial motility (2015) (9)
T‐T cell interactions during in vitro cytotoxic T cell responses. VI. The role of T cell‐derived colony‐stimulating factor in helper T cell activation (1984) (9)
Tumor necrosis factor (TNF) alpha: control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition (1987) (9)
Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein (2019) (8)
CELL‐MEDIATED IMMUNITY TO H‐2 ANTIGENS: Characteristics of the Effector Cells as Detected in the Microcytotoxicity Assay (1976) (8)
Systemische versus lokale Therapie mit rekombinantem Tumor-Nekrose-Faktor-alpha (r-TNF-alpha) bei Patienten mit fortgeschrittenen Tumoren (1989) (8)
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells (2018) (8)
Continuous infusion of an agonist of the tumor necrosis factor receptor 2 in the spinal cord improves recovery after traumatic contusive injury (2019) (8)
TNFR-Associated Factor 2 and Is Specific for TNFR 60-Induced Cell Death Is Mediated by TNFR 80-Dependent Enhancement of Scheurich and (1998) (7)
Specific membrane receptors for human interferon-gamma (IFN-gamma). (1987) (7)
Agonistic and Antagonistic Antibodies as a Tool to Study the Functional Role of Human Tumor Necrosis Factor Receptors (1993) (6)
Anti H-2Dd alloreactivity mediated by herpes-simplex-virus specific cytotoxic H-2k T lymphocytes is associated with H-2Dk (2005) (6)
Postnatal development of functional T cell subsets in the mouse: a frequency analysis of mitogen reactive precursors of proliferating, of cytotoxic and of IL 2 producing T cells. (1985) (6)
Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans (2018) (6)
Anti-TNFR 1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis (2018) (6)
The Role of T Cells in Anti-Herpes Simplex Virus Immunity (1977) (6)
Generation of Cytotoxic T Lymphocytes Against Ly Alloantigen (1977) (5)
Virion antigens introduced exogeneously into the cell membrane render syngeneic target cells susceptible for T cell-mediated cytolysis. (1977) (5)
Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice (2016) (4)
Expression of complete human IFN-gamma receptor and its extracellular domain in insect cells: purification and characterization of the recombinant proteins. (1994) (4)
Tumor Necrosis Factor and Lymphotoxin-Induced Signal Pathways (1992) (4)
Cell-mediated immunity in lumphocytic choriomeningitis. I. The specificity of the cytotoxic T lymphocytes. (1976) (4)
Tumor necrosis factor inhibits MYC expression in HL-60 cells at the level of mRNA transcription ( cytokines / gene expression ) (4)
MLs-locus-dependent mixed lymphocyte reactions result in the production of interleukin 2 activity (1981) (4)
Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F–induced disease (2021) (3)
Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF (2023) (3)
Functional analysis of Il-2 produced by T-cell hybridomas: Il-2 promotes T-cell growth but does not mediate T-cell or B-cell maturation and differentiation. (1982) (3)
IFN-gamma receptors on human tumor cells: relationship between receptor ligand interactions and induction of IFN-gamma response. (1986) (3)
Über Liptauer Käse (1912) (3)
Anti-Tumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma (2013) (3)
Mechanisms of TNF resistance: identification of membrane phosphoproteins associated with a dominant resistant phenotype in lymphoid-myeloid somatic cell hybrids. (1988) (3)
PKD controls actin polymerization and cell motility through phosphorylation of cortactin (2010) (3)
Genetic engineering of death ligands for improvement of therapeutic activity. (2011) (2)
Stable expression of a selectable myeloproliferative sarcoma virus in murine T lymphocyte and monocyte cell lines. (1987) (2)
Analysis of interleukin 2 receptor sites on activated T cells. (1983) (2)
Beitrag zur Kreatininbestimmung (1922) (2)
N-glycosidase treatment of Colo 205 cells interferes with hIFN-gamma induced HLA-DR expression. (1989) (2)
Untersuchungen über Käse des Handels (1912) (2)
[Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors]. (1989) (2)
The cytotoxic activity of mouse T lymphocytes against allogeneic cytotoxic T cells. (1975) (2)
Improving T-Cell Immunotherapies for Solid Tumors by Targeting the Tumor Stroma (2011) (2)
[Monoclonal antibodies in cancer therapy]. (1985) (1)
Regulation of Major Histocompatibility Complex Class I Gene Expression in Oncogene-Transformed Mouse Fibroblasts1 (1994) (1)
Fleisch- und Wurstwaren (1)
A bivalent immunoadhesin of the human interferon-gamma receptor is an effective inhibitor of IFN-gamma activity. (1995) (1)
Biological and biochemical characterization of a somatostatin-producing human carcinoma established by heterotransplantation. (1985) (1)
TNFR1 Blockade Rather then TNFR2 Blockade Reduces Chronic Inflammation in JAK2+/V617F Mice (2019) (1)
infected Target cells. (1977) (1)
Monoklonale Antikörper in der Krebstherapie (2008) (1)
W-04 PBPK Modeling to Guide Experimental Design in Drug Development (2015) (1)
Vom Tumornekrosefaktor zum TRAIL-AMAIZe: Antitumoral wirksame Zytokine der zweiten Generation (2001) (1)
HIGH AFFINITY HUMAN IFN-7-BINDING CAPACITY I S ENCODED BY A SINGLE RECEPTOR GENE LOCATED IN PROXIMITY TO cros ON HUMAN CHROMOSOME REGION 6 q 16 TO 6 q 22 l (2001) (1)
Nanoparticles having immobilized thereon biologically active TNF (2001) (0)
Analysis of lymphokine producing T helper cells at the clonal level. (1983) (0)
Biological Response Modifiers: Mechanisms of Action (1989) (0)
Ligand and Glucocorticoid-Induced TNF Receptor Soluble Trimers of CD 27 L , CD 40 L , 41 BBL , Immobilization Improve the Activity of Antibody-Mediated Cell Surface Trimer Stabilization , Oligomerization , and Wajant (2009) (0)
Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2 (2017) (0)
PS1443 BLOCKADE OF TNFR1 RATHER THAN TNFR2 IMPROVES HEMATOCRIT AND REDUCES BLOOD PRO-INFLAMMATORY CYTOKINE LEVELS IN THE VAV1-CRE X JAK2+/V617F MPN MOUSE MODEL (2019) (0)
Tumor Necrosis Factor and Lymphotoxin Gene Expression in Human Tumor Cell Lines 1 (2006) (0)
Short-Term Treatment withGamma Interferon InducesStable Reversion ofras-Transformed MouseFibroblasts (1991) (0)
Mitogen induced expansion of t cells under limiting dilution conditions analysis of specificity and function of selected t cell populations at the clonal level (1982) (0)
Neuigkeiten für die klinische Praxis (1984) (0)
Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine (2002) (0)
Onkologie-Mitteilungen Valet (1986) (0)
Zielgerichtete Apoptoseinduktion im hepatozellulären Karzinom durch neues TRAIL-Fusionsprotein in Kombination mit Bortezomib (2013) (0)
Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug (2001) (0)
Über die Untersuchung von Butter und Margarine (1910) (0)
Activation locale selective de membres de la famille des ligands tnf par des proteines hybrides de ligands tnf non-anticorps systemiquement inactives (2003) (0)
Die Rolle des Monozyten/Makrophagensystems bei der chronischen Polyarthritis (1990) (0)
Interferone und Onkogene (1990) (0)
Zielgerichtetes TRAIL induziert in Kombination mit Bortezomib Apoptose im hepatozellulären Karzinom jedoch nicht im Lebergewebe von Patienten mit nicht maligner entzündlicher Lebererkrankung (2013) (0)
Band 24, Supplement 1, Februar 2001 (2001) (0)
Über das Verhalten des Salpeters in Hackfleisch (1923) (0)
Interferonrezeptoren maligner Tumoren und ihre mögliche Bedeutung für die Interferontherapie (1986) (0)
Frequency-Analysis of Precursors of Cytotoxic T Lymphocytes in Radiation Chimeras: Enumeration of Antigenspecific CTL-P Restricted to Thymic MHC- and Bone Marrow-MHC-Determinants (1984) (0)
REGULATION OF HUMAN T CELL RESPONSES BY GAMMA INTERFERON (IFN-γ): STUDIES ON THE BINDING AND BIOLOGICAL EFFECTS OF IFN-γ ON DISTINCT T CELL SUBPOPULATIONS1 (1985) (0)
Differential7-lnterferon Responseof HumanColonCarcinomaCells: Inhibition of Proliferationand Modulationof Immunogenicityas IndependentEffects of 7-lnterferon on TumorCell Growth1 (2006) (0)
IgG-single-chain TRAIL fusion proteins for tumour therapy (2018) (0)
Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis (2023) (0)
T-T-cell interactions during in vivo responses to transplantation antigens. (1977) (0)
Functional Analysis of Alloreactive Helper T Cells Involved in the Induction of Cytolytic T Cell Responses In Vitro (1984) (0)
TNF RECEPTOR 2 SIGNALING : A TARGET FOR THERAPEUTIC INTERVENTIONS AGAINST NEURODEGENERATIVE DISEASES? (2011) (0)
TNFR2 protects from excitotoxic neuronal death via PI3 kinase signalling pathways (2003) (0)
Cell type specific expression of tumor necrosis factor-a in the CNS and pituitary of transgenic mice (1998) (0)
Independent regulation of tumor necrosis factor and lymphotoxin gene expression in human tumor cells (1988) (0)
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis (2018) (0)
Shared determinants between virus-infected and trinitrophenyl-conjugated H-2-identical target cells detected in cel Imed iated (2005) (0)
Tnf-mediated inhibition of transformation of mouse fibroblasts correlates with down-regulation of oncogene expression (1987) (0)
Preparation of IL-2 Batches (2003) (0)
Abstract PR16: Genetically engineered T cells redirected against cancer-associated fibroblasts to potentiate immunotherapeutic effects. (2013) (0)
Responses. V. Precursor frequencies and specificity of alloreactive helper t cells. (1982) (0)
Genetic engineering of a TNFR2 agonist to promote immunomodulation and neuroprotection (2014) (0)
Endothelial Cells Barrier Breakdown in Human Brain Role of Caspases in Cytokine-Induced (2012) (0)
The in vitro induction of antigen-specific cytotoxic T lymphocytes (CTL) 1 requires the collaboration between functionally dintinct T cell subpopulations (1-5). Studies at the population level have revealed that upon antigen-specific activation, helper T lymphocytes (HTL) release nonspecific mediato (2003) (0)
Phylogeny and catalytic mechanism of hydroxynitrile lyases (1996) (0)
Escherichia coli Expression in Overcomes the Limitations of Periplasmic Leads to Active Product and mirabilis Proteus Secretion in L-Form Cells of Variable-Fragment ( scFv ) Antibodies : Procaryotic Expression of Single-Chain (1998) (0)
Mechanisms of TNF Action: Analysis of Receptor Structure and of Regulatory Circuits Controlling Receptor Expression and TNF Production (1990) (0)
SELECTIVE ANTAGONISTS huTNFR1. (2007) (0)
Biological effects and specific membrane receptors for IFN-γ and for tumor necrosis factor on human tumor cells (1986) (0)
Oligoclonality of non-Hodgkin's lymphoma established by analysis of immunoglobul in gene rearrangements (1986) (0)
Abstract #4178: Immunosuppressive role of antiestrogen induced TGF-ß in breast cancer (2009) (0)
RECOMBINANT TUMOR-NECROSIS-FACTOR (RTNF) INDUCES TNF MESSENGER-RNA ACCUMULATION IN HL60 CELLS (1986) (0)
OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments. (2018) (0)
Mls locus coded determinants stimulate the release of interleukin 2 activity from t lymphocytes (1980) (0)
Novel TRAIL variants for targeted cancer therapy. (2010) (0)
Herpes-simplex-virus-specific, H-2Dk-restricted T lymphocytes bear receptors for H-2Dd alloantigen (2005) (0)
Cold adaptive short term effects on shivering threshold in the cold adapted and non-cold-adapted guinea pig (1982) (0)
Influence of recombinant human interferon-gamma on platelet function and coagulation factors in vitro and in patients treated for hematolocig malignancies (1986) (0)
[Molecular biology in tumor diagnosis. New ways for the detection, classification and staging of malignant lymphomas]. (1986) (0)
Rearrangements of T cell receptor genes and expression of high affinity IL-2 receptors in an EBV transformed B cell line (1986) (0)
Enhanced Stability and Antitumoral Activity Single-Chain TNF, a TNF Derivative with (2013) (0)
Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS (2023) (0)
Regulation of TNF sensitivity via receptor modulation controlled by protein kinase c (1987) (0)
Tumour stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumours (2019) (0)
T cell-mediated cytotoxic immune response to HSV infection and its modification due to antimetabolites. (1979) (0)
Monoclonal antibody, protein having characteristic of antibody, hybridoma cell system and production of monoclonal antibody (1991) (0)
[From tumor necrosis factor to TRAIL-AMAIZe: second generation antitumorally effective cytokines]. (2001) (0)
Control of TNF Receptor Expression and Function by Protein Kinases (1990) (0)
“Allogeneic factor like” activity produced by T-cells reactive to hapten-modified syngeneic MHC-structures☆☆☆ (1976) (0)
Tumor necrosis factor inhibits MYC expression in HL-60 cells at the (2016) (0)
TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice (2020) (0)
Human Tumor Cells-Interferon Receptors on γ Quantitation and Characterization of Updated Version (2006) (0)
Control of TNF Sensitivity via Regulation of TNF Receptor Expression1 (1988) (0)
An antibody-TNF TNF inhibitor fusion protein (TNF-Selektokin) as target-specific for tumor therapy Prozytokin (2000) (0)
Medicament to increase the efficacy of a receptor-mediated triggering apoptosis in tumor cells the drug (2002) (0)
Translating TNFR signalling into neuroprotective strategies: Proof of concept in acute in vivo models of neurodegeneration using humanized TNFR mice (2016) (0)
Activation localement specifique, par l'intermediaire d'anticorps, d'une zytokine pro-apoptose : amaize (antibody-mediated apoptosis inducing zytokine) (2001) (0)
Activation mediated proapoptotic cytokine specific antibodies to the site; AMAIZe (apoptosis-inducing cytokines antibody mediated) (2001) (0)
Clonal rearrangements of T-cell receptor and immunoglobul in genes as sensitive marker for bone marrow involvement in non-Hodgkin's lymphoma (1986) (0)
Differential Regulation of Cell Membrane Receptors for Interferon-γ and -α on Peripheral Blood Cells of Patients with Chronic Myelogenous Leukemia During Interferon-γ/α Therapy (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klaus Pfizenmaier?

Klaus Pfizenmaier is affiliated with the following schools:

Klaus Pfizenmaier's Academic­Influence.com Rankings

Klaus Pfizenmaier's Degrees

Similar Degrees You Can Earn

Why Is Klaus Pfizenmaier Influential?

Klaus Pfizenmaier's Published Works

Published Works

What Schools Are Affiliated With Klaus Pfizenmaier?

Klaus Pfizenmaier's AcademicInfluence.com Rankings